Estradiol and drospirenone for climacteric symptoms in postmenopausal women: A double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens

Climacteric

Volumn 7, Issue 2, 2004, Pages 189-196

  Schurmann R ^a   Holler, T ^a   Benda, N ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Climacteric symptoms; Drospirenone; Estradiol; Postmenopause

Indexed keywords

DROSPIRENONE; ESTRADIOL; PLACEBO;

ADENOMYOSIS; ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LABORATORY TEST; LEIOMYOMA; MAJOR CLINICAL STUDY; MASTALGIA; MENOPAUSAL SYNDROME; MULTICENTER STUDY; NERVOUSNESS; POLYP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SWEATING; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; UTERINE CERVIX TUMOR;

AGED; ALDOSTERONE ANTAGONISTS; ANDROSTENES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 3242664107     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130410001713698     Document Type: Article

References (12)

1. MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001;4:58-74
2. Witt DM, Lousberg TR. Controversies surrounding estrogen use in postmenopausal women. Ann Pharmacother 1997;31:745-55
3. Linzmayer L, Semlitsch HV, Saletu B, et al. Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung 2001;51:238-45
4. Whitehead MI, Townsend PT, Pryse-Davies J, et al. Actions of progestins on the morphology and biochemistry of the endometrium of postmenopausal women receiving low-dose estrogen therapy. Am J Obstet Gynecol 1982;142:791-5
5. Ettinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term, unopposed estrogen replacement therapy. Maturitas 1988;10:271-82
6. Corson SL, Richart RM, Caubel P, Lim P. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17beta-estradiol and norgestimate on endometrial histology. Int J Fertil Womens Med 1999;44:279-85
7. Cust MP, Gangar KF, Hillard TC, Whitehead MI. A risk-benefit assessment of estrogen therapy in postmenopausal women. Drug Saf 1990;5:345-58
8. Laurent H, Bittler D, Hofmeister H, et al. Synthesis and activities of anti-aldosterones. J Steroid Biochem 1983;19:771-6
9. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-35
10. Follow K, Juchem M, Elger W, Jacobi N, Hoffman G, Möbus V. Dihydrospirorenone (ZK30595): a novel synthetic progestagen - characterization of binding to different receptor proteins. Contraception 1992;46:561-74
11. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51
12. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21